| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,510 | 1,528 | 16:39 | |
| 1,510 | 1,528 | 16:39 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OSE IMMUNOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.10. | OSE Immunotherapeutics Reports Additional Positive Results of Combi-TED Phase 2 Randomized Trial with Tedopi (OSE2101) in metastatic Non-Small Cell Lung Cancer | 3 | GlobeNewswire (USA) | ||
| 20.10. | OSE Immunotherapeutics auf der 10. Annual Healthcare Conference von Chardan: Finanzierungsengpass trifft auf klinische Fortschritte | 1 | Investing.com Deutsch | ||
| 19.10. | OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi (OSE2101) in metastatic Non-Small Cell Lung Cancer | 2 | GlobeNewswire (USA) | ||
| 28.09. | OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update | 303 | GlobeNewswire (Europe) | €11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026The Company continues to engage actively with institutional investors in the United States and Europe to... ► Artikel lesen | |
| 23.09. | OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting | 3 | GlobeNewswire (USA) | ||
| 09.09. | OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients | 670 | GlobeNewswire (Europe) | Nantes, France, September 9, 2026 - 6pm CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company") welcomes the announcement by its licensee Veloxis Pharmaceuticals, Inc. that... ► Artikel lesen | |
| 28.08. | OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026 | 3 | GlobeNewswire (USA) | ||
| 08.07. | OSE Immunotherapeutics: Half-Year Report on Liquidity Contract with Invest Securities | 4 | GlobeNewswire (USA) | ||
| 03.06. | OSE Immunotherapeutics: Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting | 6 | GlobeNewswire (USA) | ||
| 03.06. | OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document | 284 | GlobeNewswire (Europe) | 2025 Audited financial statements are consistent with Unaudited financial statements previously reported on April 30, 2026The IRIS Financing announced on May 28, 2026, was added as a subsequent eventConfirmed... ► Artikel lesen | |
| 28.05. | OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing | 419 | GlobeNewswire (Europe) | First step of a global financing strategy, as the Company is actively engaging with institutional investors in the United States and in EuropeGross proceeds could amount to €19.3 million based on... ► Artikel lesen | |
| 22.05. | OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi in Recurrent Ovarian Cancer | 421 | GlobeNewswire (Europe) | OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer Topline results to be presented by Alexandra Leary, MD, PhD, on May 30, 2026... ► Artikel lesen | |
| 30.04. | OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position | 547 | GlobeNewswire (Europe) | OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi®1€22.7 and €17.0 million cash position as of December 31, 2025, and... ► Artikel lesen | |
| 27.04. | OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients | 437 | GlobeNewswire (Europe) | Nantes, France, April 27, 2026 - 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today welcomes the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S.... ► Artikel lesen | |
| 14.04. | OSE Immunotherapeutics Evolves its Leadership Team | 527 | GlobeNewswire (Europe) | OSE Immunotherapeutics Evolves its Leadership Team Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively Nantes, France, April 14, 2026 - 6:00pm CEST - OSE Immunotherapeutics... ► Artikel lesen | |
| 10.03. | OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth | 278 | GlobeNewswire (Europe) | Nantes, France, March 10, 2026 - 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive... ► Artikel lesen | |
| 03.03. | OSE Immunotherapeutics - Reaffirmed dedication to core assets | 746 | Edison Investment Research | OSE Immunotherapeutics has reaffirmed its strategy of streamlining its clinical pipeline following some developments to its partnered assets. For ABBV-230 (OSE-230), partnered with AbbVie, OSE had previously... ► Artikel lesen | |
| 02.03. | OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi | 506 | GlobeNewswire (Europe) | Streamlining of selected non-strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic planNo impact on cash runway or financing strategy as no... ► Artikel lesen | |
| 26.02. | OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi in Non-Small Cell Lung Cancer | 732 | GlobeNewswire (Europe) | NANTES, France, February 26, 2026 - 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that the Independent Data Monitoring Committee (IDMC) has issued a second... ► Artikel lesen | |
| 29.01. | OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab | 356 | GlobeNewswire (Europe) | OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationaleChronic Pouchitis offers... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 75,35 | -1,63 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| EVOTEC | 2,728 | 0,00 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| BB BIOTECH | 57,60 | 0,00 % | Christian Koch, Leiter BB Biotech Team bei Bellevue Asset Management, im Interview | von Robert Jakob Moneycab.com: Herr Koch, acht bestehende Beteiligungen verkauft, zwölf neue Positionen aufgebaut, das sieht nach einer grösseren Rochade aus? Die Veränderungen spiegeln unser aktives... ► Artikel lesen | |
| MEDIGENE | 0,003 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| MODERNA | 176,48 | -1,56 % | Moderna, Bayer, Merck investieren Milliarden - doch bei Psychedelika fehlt ein entscheidendes Teil | ||
| AMGEN | 400,55 | -0,94 % | Piper Sandler raises Amgen stock price target on pipeline potential | ||
| VALNEVA | 2,470 | +1,19 % | Valneva im Check: Starke Shigella-Daten - reicht der Schwung? | ||
| NOVAVAX | 7,160 | -1,24 % | Novavax: Warum der Zahlen-Erfolg nicht alle überzeugt | ||
| STRYKER | 285,10 | -1,66 % | Stryker: 178,92-Millionen-Verkauf - was steckt dahinter? | ||
| BIOGEN | 226,20 | -1,22 % | 10,7 Billionen Dollar (!) Schaden: Lilly, Biogen, Jazz Pharmaceuticals und NeuroThera greifen in diesem Markt an! | ||
| BIOFRONTERA | 2,770 | -4,81 % | Biofrontera AG: Liquiditätsdruck - was Anleger prüfen müssen | ||
| HEIDELBERG PHARMA | 2,070 | +1,47 % | Formycon, Heidelberg Pharma, Medios: Wo Analysten das meiste Potenzial sehen | ||
| ILLUMINA | 194,88 | +1,88 % | Illumina Stock Surges 74.8% in a Year: What's Fueling the Drive? | ||
| CG ONCOLOGY | 83,37 | +4,21 % | Guggenheim raises CG Oncology stock price target on trial results |